Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Harvey A Tatum"'
Autor:
Reem Ghalib, Michelle Treitel, Claudia Martorell, Harvey A Tatum, J. Hanson, Paul J. Thuluvath, E. Cooney, Natarajan Ravendhran, J. Zhao, Vinod K. Rustgi, M. Demicco, J. Zamparo, Eric Lawitz, S. Cohen, Eric Hughes
Publikováno v:
Journal of Viral Hepatitis. 22:658-664
Beclabuvir is a potent, non-nucleoside inhibitor of the HCV NS5B RNA polymerase, with nanomolar activity against HCV genotypes 1, 3, 4, 5 and 6 in vitro. This study evaluated the efficacy and safety of beclabuvir, in combination with peginterferon al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97082f374be76a6fab395923d1320574
https://doi.org/10.1111/jvh.12372
https://doi.org/10.1111/jvh.12372
Autor:
Paul J. Thuluvath, Paul Y. Kwo, Harvey A Tatum, John M. Vierling, Paul J. Pockros, Stanislas Pol, Fiona McPhee, Megan Wind-Rotolo, Ola Weiland, Nina Weis, Philip D. Yin, William Sievert, Eric Hughes, Gideon M. Hirschfield, Maribel Rodriguez-Torres, Eric Lawitz, Vinod K. Rustgi, Stephen D. Shafran, Mark S. Sulkowski, Stefan Zeuzem, Gamal Esmat, Marc Bourlière, Gregory T. Everson, Dennis Hernandez, Lawrence Serfaty, Zhaohui Liu, Imam Waked, Wayne Ghesquiere, Michael W. Fried, Steven Schnittman, Maurizia Rossana Brunetto, Stephanie Noviello, Christophe Hézode, Norbert Bräu
Publikováno v:
Gut. 64(6)
To evaluate the safety and efficacy of daclatasvir, an HCV NS5A inhibitor with pangenotypic activity, administered with peginterferon-alfa-2a/ribavirin.In this Phase 2b double-blind, placebo-controlled study, treatment-naive adults with HCV genotype
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfb2e43051dbf5fe96d2c62fa22faa37
https://pubmed.ncbi.nlm.nih.gov/25080450
https://pubmed.ncbi.nlm.nih.gov/25080450
Autor:
David W. Morris, Dennis Hernandez, Stanislas Pol, Robert Reindollar, Jean-Pierre Bronowicki, Ulysses Diva, Gary A Abrams, Joseph K. Lim, Norbert Bräu, R. Hindes, Christophe Hézode, Steven Schnittman, Megan Wind-Rotolo, Reem Ghalib, Eric Hughes, Vinod K. Rustgi, Paul J. Thuluvath, Harvey A Tatum, Claudia Martorell, Fiona McPhee, G.T. Everson, Philip D. Yin
Publikováno v:
The Lancet. Infectious diseases. 12(9)
Summary Background Several direct-acting antivirals for chronic hepatitis C virus (HCV) infection are available, but they are limited by tolerability and dosing schedules. Once-daily daclatasvir, a potent NS5A replication complex inhibitor, was gener
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6605128c35ef3d4f5d08e58ee1831bce
https://pubmed.ncbi.nlm.nih.gov/22714000
https://pubmed.ncbi.nlm.nih.gov/22714000
Autor:
William M. Lee, Timothy J Friel, Laura Kriebel, Geraldine B. Guillon, Mark Fischl, Alexander Monto, Keith W. Kardos, Lisa A. Kurtz, Eugene R. Schiff, Scott E. Eder, Jay Lynn Unangst, Cheryl A. Berne, Alpha T. Banks, Karam Mounzer, Harvey A. Tatum, Michael P. DeMicco, Stephen R. Lee, Gary Feiss, Michele Roehler, Graham Yearwood
Publikováno v:
Journal of virological methods. 172(1-2)
The availability of a highly accurate, rapid, point-of-care test for hepatitis C virus (HCV) may be useful in addressing the problem of under-diagnosis of HCV, by increasing opportunities for testing outside of traditional clinical settings. A new HC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9eb9726a393288487efd302aba216fc0
https://pubmed.ncbi.nlm.nih.gov/21182871
https://pubmed.ncbi.nlm.nih.gov/21182871
Autor:
Scott Fung, Fiona McPhee, Stanislas Pol, Serena Zaltron, Alnoor Ramji, Victor de Ledinghen, David Cohen, Harvey A Tatum, Stephen D. Shafran, Dominique Larrey, Christophe Hézode, Gloria Taliani, E. Cooney, Peggy Hagens, Nina Weis, Albert Tran, Hugh Harley, Maurizia Rossana Brunetto, Stephanie Noviello, Samuel S. Lee, Gregory J. Dore, Wayne Ghesquiere, Eric Lawitz, Eric Hughes, Simone I. Strasser, Dennis Hernandez, Jacob George
Publikováno v:
Gastroenterology
Gastroenterology, WB Saunders, 2015, 148 (2), pp.355-366.e1. ⟨10.1053/j.gastro.2014.10.007⟩
Gastroenterology, Elsevier, 2015, 148 (2), pp.355-366.e1. ⟨10.1053/j.gastro.2014.10.007⟩
Gastroenterology, WB Saunders, 2015, 148 (2), pp.355-366.e1. ⟨10.1053/j.gastro.2014.10.007⟩
Gastroenterology, Elsevier, 2015, 148 (2), pp.355-366.e1. ⟨10.1053/j.gastro.2014.10.007⟩
International audience; BACKGROUND & AIMS:Twenty-four weeks of treatment with peginterferon and ribavirin for chronic hepatitis C virus (HCV) genotype 2 or 3 infection produces a sustained virologic response (SVR) in 70%-80% of patients. We performed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bd54b53b397953c4873b0b0e579d226
https://doi.org/10.1053/j.gastro.2014.10.007
https://doi.org/10.1053/j.gastro.2014.10.007
Autor:
G.J. Dore, Stephen D. Shafran, Nina Weis, Maurizia Rossana Brunetto, Simone I. Strasser, Scott Fung, Daniel Cohen, P. Hagens, Alnoor Ramji, Serena Zaltron, Wayne Ghesquiere, Stanislas Pol, Eric Hughes, E. Lawitz, Harvey A Tatum, E. Cooney, Dominique Larrey, Hugh Harley, Stephanie Noviello, Albert Tran, Christophe Hézode, Gloria Taliani, Jacob George, V. de Ledinghen, Samuel S. Lee
Publikováno v:
Journal of Hepatology. 58:S570-S571
All study medications were discontinued due to adverse events (AEs) in 4%, 4% and 5% of patients, and FDV only was discontinued in 0%, 1% and 3% of patients, respectively. Serious AEs occurred in 6%, 7% and 7% of patients. Grade 3 rash occurred in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e88720d846859b1c648736ae43df314a
https://doi.org/10.1016/s0168-8278(13)61417-8
https://doi.org/10.1016/s0168-8278(13)61417-8
Autor:
Vinod K. Rustgi, K. Sims, Ellen Chung, David F. Gardiner, Harvey A Tatum, Dennis M. Grasela, Christophe Hézode, Fiona McPhee, Timothy Eley, Maribel Rodriguez-Torres, Megan Wind-Rotolo, M. Bourlière, Claudio Pasquinelli, Véronique Loustaud-Ratti, X. Wang, G.T. Everson, E.J. Lawitz, Howard J. Schwartz, Shu-Pang Huang, Stanislas Pol, Paul J. Thuluvath, Patrick Marcellin
Publikováno v:
Journal of Hepatology. 58:S573
13.6±1.8 g/dL [8.8–17.5], respectively. After 12W, a complete early virological response was obtained in 34 (83%) boceprevir patients and in 35 (61%) telaprevir patients (p = 0.026). Among 17 boceprevir and 16 telaprevir patients, 14 (82%) and 7 (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6532c8d7b22257e127441b2536003239
https://doi.org/10.1016/s0168-8278(13)61422-1
https://doi.org/10.1016/s0168-8278(13)61422-1
Publikováno v:
International Journal of Systematic Bacteriology. 22:19-38
Sixty-two strains of moraxellae and allied bacteria assembled by the Subcommittee on Moraxella and Allied Bacteria of the International Committee on Systematic Bacteriology and distributed by the American Type Culture Collection were examined serolog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4d8e10db29785f79637861e83608accc
https://doi.org/10.1099/00207713-22-1-19
https://doi.org/10.1099/00207713-22-1-19
Autor:
Elizabeth O. King, Harvey W. Tatum
Publikováno v:
The Journal of Infectious Diseases. 111:85-94
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3731ac14d4dafe6ebdb01ce2cc9559d3
https://doi.org/10.1093/infdis/111.2.85
https://doi.org/10.1093/infdis/111.2.85
Publikováno v:
Canadian Journal of Microbiology. 18:1477-1482
Pseudomonas acidovorans can be distinguished from P. testosteroni by gas chromatography on the basis of acids detected after 20 h growth on heart infusion agar plates. The data obtained support the findings of other workers that P. acidovorans and P.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2910e5f0285e4bc99379fd766b01bfe0
https://doi.org/10.1139/m72-226
https://doi.org/10.1139/m72-226